Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Adopted by German Lighting Brand WALTRON for Aquarium Lighting
29.10.2019 20:08:00 EET | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that WALTRON, specialists in LED lighting systems for aquariums and terrariums based in Lower Saxony, Germany, has adopted Seoul Semiconductor’s SunLike Series natural spectrum LEDs for daytime® Pendix, WALTRON’s aquarium lighting solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191029005896/en/
Seoul Semiconductor’s SunLike Series natural spectrum LEDs for aquarium lighting of German brand WALTRON (Photo: Business Wire)
Indoor aquariums are full of colorful corals, fish, and water plants living in an ecosystem similar to nature. Direct sunlight is typically avoided in these spaces in order to limit the reproduction of algae. This is necessary to keep water from becoming turbid and harming the ecological balance of the aquarium system. As a result, lighting solutions play an important role in maintaining growth without disturbing the ecological cycle.
The daytime Pendix is a matrix LED module with 9 different color temperatures and features a customized spectral lighting design that closely matches the spectrum of natural sunlight enabled by SunLike Series LEDs. Different light colors such as white, blue, and red can be combined in the module to provide the optimal lighting solution for both saltwater aquariums and freshwater aquariums.
Sunlight has always played an important role with plant growth in nature. SunLike Series natural spectrum LEDs are similar to sunlight which radiate a uniform amount of energy at all wavelengths, including infrared and ultraviolet as the optimal light source for plant growth. The technology lowers the light peaks of red, green and blue to be more similar to sunlight’s spectral curve in order to provide a better growth formula than what is common in conventional LEDs. This results in a more natural and healthy environment for fish, plants, and corals while further decreasing algae growth on glass.
Light sources with SunLike Series LEDs more accurately show the color of objects as they would appear in natural sunlight. Optimized to natural light spectra and color rendering of CRI-97 (close to CRI-100 of sunlight), and higher than the CRI-80 of conventional LEDs, SunLike Series LEDs deliver more significant benefits in vivid color, contrast detail, and quality of light consistency. These qualities can be vital to aquariums, enabling the owners to more accurately observe and attend to the overall growth and health status of fish.
“We are pleased to expand this aquarium LED lighting portfolio. Our SunLike Series natural spectrum LEDs as healthy light sources will offer the considerable benefits for better growth of fishes and plants in aquarium, compared to conventional LEDs,” said Carlo Romiti, Europe sales Vice President of Seoul Semiconductor. “Seoul Semiconductor will continue to support the needs of customers with a range of innovative LED lighting solutions.”
Seoul Semiconductor developed SunLike Series natural spectrum LEDs in collaboration with Toshiba Materials’ TRI-R spectrum technology in 2017 as the first LED light source to closely match the spectrum of natural sunlight.
To learn more about daytime Pendix by WALTRON, please visit:
http://daytime.de/led-systeme-pendix
To learn more about the SunLike Series natural spectrum LEDs, please visit: http://www.seoulsemicon.com/en/technology/Sunlike/
# # #
About WALTRON
WALTRON specializes in innovative LED lighting systems that highlight the natural beauty of animals and plants in aquariums and terrariums brilliantly. Its daytime® brand delivers lighting solutions for the demanding aquarium owner. We invite you to discover the many possibilities of the daytime® product lines: matrix, eco, cluster and cluster control. For more information, please visit http://daytime.de/.
About Seoul Semiconductor
Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 14,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity and cost savings at the fixture level, providing high lumen density and design flexibility; NanoDriver Series – the world’s smallest 24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, including all AC LED-related technologies from chip to module and circuit fabrication, and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC. For more information, please visit www.seoulsemicon.com/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191029005896/en/
Contact information
Seoul Semiconductor Inc.
Jeonghee Kim
Tel: +82-70-4391-8311
Email: jeonghee.kim@seoulsemicon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom